A Study Comparing Outcomes of Kidney Transplants in Patients on Steroids Versus Those Who Discontinue Steroids
A Study Comparing Outcomes of Kidney Transplants in Patients on Steroids Versus Those Who Discontinue Steroids
The purpose of this study is to compare the risks and benefits of steroid elimination versus
 steroid therapy in renal transplant patients particularly looking at the effects on bone
 mass, lipids, hypertension, and new onset diabetes.
The use of steroids after renal transplantation has been invaluable, resulting in higher
 rates of long term survival of the transplanted kidney. However, post-operative steroids are
 also associated with frequent post-operative and long term complications. There have been
 steroid elimination studies analyzing acute rejection rates, graft and patient survival.
 These studies show that many patients can safely have steroids withdrawn with equivalent
 results whan compared to those who remain on steroids.

 With this study we will be using a rapid steroid elimination protocol for 40 patients and
 compare 20 patients who remain on steroids. We hope to show a decreased rate of complications
 such as osteopenia/osteoporosis, new onset diabetes, and a decrease in cardiovascular risk
 factors such as hyperlipidemia and hypertension.

 Solumedrol will be given to all patients at the time of transplant followed by a prednisone
 taper. Those remaining on steroids will be discharged on prednisone 5 mg daily. Those in whom
 steroids are eliminated will be off prednisone by discharge.
Inclusion Criteria:

 -  Patients undergoing a single renal transplant from deceased or living donor

 -  Adults 18 years and older

 -  First or second renal transplant

 -  Capable of understanding the purposes of the study, has given written informed
 consent, and agrees to comply with the study requirements

 -  Women of child bearing age should have a negative serum pregnancy test

 Exclusion Criteria:

 -  Greater than 2 renal transplants

 -  Age < 18 years

 -  Patients receiving immunosuppressive therapy within the preceding 28 days for first
 transplant and 3 months for the second transplant

 -  Cold ischemia time > 30 hours

 -  History of malignancy in the last 5 years except successfully treated localized
 non-melanoma skin cancer

 -  HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) positive serology

 -  Loss of previous transplant in < 1 year

 -  History of non-compliance

 -  Any form of substance abuse, psychiatric disorder or condition which, in the opinion
 of the investigator, may impair communication with the investigator or compliance with
 study procedures

 -  Multiple organ transplant

 -  History of chronic steroid use except for inhaled steroids for asthma

 -  Pregnant or lactating females

 -  Women of childbearing potential not willing to use a reliable form of contraception.

 -  Patients with severe medical condition(s) that, in the view of the investigator,
 prohibits participation in the study

 -  Known sensitivity to study drugs or class of study drugs

 -  Use of any investigational agent in the last 30 days